抗菌肽对耐碳青霉烯类革兰阴性菌抗菌活性的研究进展  

Research progress on activity of antimicrobial peptides against carbapenem-resistant Gram-negative bacteria

作　　者：杨曜竹(综述) 牛敏[1] 杜艳(审校)[1] YANG Yaozhu;NIU Min;DU Yan(Department of Clinical Laboratory,the First Affiliated Hospital of Kunming Medical University,Yunnan Key Laboratory of Laboratory Medicine,Yunnan Province Clinical Research Center for Laboratory Medicine,Kunming 650032,Yunnan Province,China)

机构地区：[1]昆明医科大学第一附属医院医学检验科、云南省检验医学重点实验室、云南省医学检验临床医学研究中心,云南昆明650032

出　　处：《微生物学免疫学进展》2023年第4期67-71,共5页Progress In Microbiology and Immunology

基　　金：云南省科技厅昆医联合专项(202001AY070001-037)。

摘　　要：耐碳青霉烯类革兰阴性菌(carbapenem-resistant Gram-negative bacteria,CRGNB)是医院感染常见的耐药致病菌,主要包括耐碳青霉烯类肺炎克雷伯菌(carbapenem-resistant Klebsiella pneumoniae,CRKP)、耐碳青霉烯类铜绿假单胞菌(carbapenem-resistant Pseudomonas aeruginosa,CRPA)和耐碳青霉烯类鲍曼不动杆菌(carbapenem-resistant Acinetobacter baumannii,CRAB)等,这类细菌引起的感染临床治疗难度较大,而抗菌肽(antimicrobial peptides,AMPs)是一类用于治疗CRGNB有着很好前景的药物,能与临床上常见的抗生素联合使用,在用于CRGNB引起的感染中抗菌效果较为显著。现就AMPs的来源、抗菌机制和研究现状等作一概述。Carbapenem-resistant Gram-negative bacteria(CRGNB)are the common drug-resistant pathogens in nosocomial infections,mainly including carbapenem-resistant Klebsiella pneumoniae(CRKP),carbapenem-resistant Pseudomonas aeruginosa(CRPA)and carbapenem-resistant Acinetobacter baumanni(CRAB),etc.Infections caused by CRGNB have gradually worsened and become a major challenge in the clinical treatment.Therefore,strong countermeasures must be taken against these bacteria immediately,among them antimicrobial peptides(AMPs)are considered to be a prospective class of antibacterial agents that have shown promising results when treated to against CRGNB in combination with commonly used antibiotics.This article provides an overview of the sources,antibacterial mechanisms,and research status of AMPs.

关 键 词：抗菌肽 碳青霉烯类耐药 革兰阴性菌 来源 机制 抑菌作用 抗菌活性 

分 类 号：R446.5[医药卫生—诊断学]